Response to Reviewer 1 Comments In this manuscript, the authors, Davidi et al have investigated the effect of TTFields in HCC cells and an animal model, alone or in combination with sorafenib.
Since sorafenib acts also on angiogenesis, did the authors investigate if TTFields may interfere with anti-angiogenic effect sorafenib-mediated? Also, is there any evidence that TTF may prevent the pretty common resistance to sorafenib observed in clinic? Moreover, there is a discrepancy between the fold changes in tumor weight vs. volume in the combination group vs. untreated group. Did the authors check changes in blood vessels density. Were the mice perfused before collecting the tumors?